Alleviation of Limosilactobacillus reuteri in polycystic ovary syndrome protects against circadian dysrhythmia-induced dyslipidemia via capric acid and GALR1 signaling
From BugSigDB
Jump to:navigation, search
Study information
-
Quality control
- Retracted paper
- Contamination issues suspected
- Batch effect issues suspected
- Uncontrolled confounding suspected
- Results are suspect (various reasons)
- Tags applied
study design
Citation
PMID PubMed identifier for scientific articles.
DOI Digital object identifier for electronic documents.
URI Uniform resource identifier for web resources.
Authors
Li S, Zhai J, Chu W, Geng X, Wang D, Jiao L, Lu G, Chan WY, Sun K, Sun Y, Chen ZJ, Du Y
Journal
NPJ biofilms and microbiomes
Year
2023
Knowledge gaps that limit the development of therapies for polycystic ovary syndrome (PCOS) concern various environmental factors that impact clinical characteristics. Circadian dysrhythmia contributes to glycometabolic and reproductive hallmarks of PCOS. Here, we illustrated the amelioration of Limosilactobacillus reuteri (L. reuteri) on biorhythm disorder-ignited dyslipidemia of PCOS via a microbiota-metabolite-liver axis. A rat model of long-term (8 weeks) darkness treatment was used to mimic circadian dysrhythmia-induced PCOS. Hepatic transcriptomics certified by in vitro experiments demonstrated that increased hepatic galanin receptor 1 (GALR1) due to darkness exposure functioned as a critical upstream factor in the phosphoinositide 3-kinase (PI3K)/protein kinase B pathway to suppress nuclear receptors subfamily 1, group D, member 1 (NR1D1) and promoted sterol regulatory element binding protein 1 (SREBP1), inducing lipid accumulation in the liver. Further investigations figured out a restructured microbiome-metabolome network following L. reuteri administration to protect darkness rats against dyslipidemia. Notably, L. reuteri intervention resulted in the decrease of Clostridium sensu stricto 1 and Ruminococcaceae UCG-010 as well as gut microbiota-derived metabolite capric acid, which could further inhibit GALR1-NR1D1-SREBP1 pathway in the liver. In addition, GALR antagonist M40 reproduced similar ameliorative effects as L. reuteri to protect against dyslipidemia. While exogenous treatment of capric acid restrained the protective effects of L. reuteri in circadian disruption-induced PCOS through inhibiting GALR1-dependent hepatic lipid metabolism. These findings purport that L. reuteri could serve for circadian disruption-associated dyslipidemia. Manipulation of L. reuteri-capric acid-GALR1 axis paves way for clinical therapeutic strategies to prevent biorhythm disorder-ignited dyslipidemia in PCOS women.
Experiment 1
Reviewed Marked as Reviewed by KateRasheed on 2025-8-18
Subjects
- Location of subjects
- China
- Host species Species from which microbiome was sampled. Contact us to have more species added.
- Rattus norvegicus
- Body site Anatomical site where microbial samples were extracted from according to the Uber Anatomy Ontology
- Feces Cow dung,Cow pat,Droppings,Dung,Excrement,Excreta,Faeces,Fecal material,Fecal matter,Fewmet,Frass,Guano,Matières fécales@fr,Merde@fr,Ordure,Partie de la merde@fr,Piece of shit,Porción de mierda@es,Portion of dung,Portion of excrement,Portion of faeces,Portion of fecal material,Portion of fecal matter,Portion of feces,Portion of guano,Portion of scat,Portionem cacas,Scat,Spoor,Spraint,Stool,Teil der fäkalien@de,Feces,feces
- Condition The experimental condition / phenotype studied according to the Experimental Factor Ontology
- Polycystic ovary syndrome Cystic disease of ovaries,hyperandrogenemia,Multicystic ovaries,multicystic ovaries,Ovarian Degeneration, Sclerocystic,Ovarian Syndrome, Polycystic,Ovarian Syndromes, Polycystic,Ovaries, Sclerocystic,Ovary Syndrome, Polycystic,Ovary, Sclerocystic,PCO - Polycystic ovaries,Pco1,PCOD - Polycystic ovarian disease,PCOS,Pcos,PCOS - Polycystic ovarian syndrome,PCOS1,Polycystic ovarian disease,polycystic ovarian disease,Polycystic ovarian syndrome,Polycystic ovaries,polycystic ovaries,Polycystic ovaries (disorder),polycystic ovary,polycystic ovary syndrome,polycystic ovary syndrome 1,Sclerocystic Ovarian Degeneration,Sclerocystic Ovaries,Sclerocystic Ovary,Sclerocystic Ovary Syndrome,Stein Leventhal Syndrome,Stein-Leventhal synd.,Stein-Leventhal Syndrome,Stein-Leventhal syndrome,Syndrome, Polycystic Ovary,Syndrome, Stein-Leventhal,Polycystic ovary syndrome
- Group 0 name Corresponds to the control (unexposed) group for case-control studies
- Control
- Group 1 name Corresponds to the case (exposed) group for case-control studies
- Darkness
- Group 1 definition Diagnostic criteria applied to define the specific condition / phenotype represented in the case (exposed) group
- Rats in this group were exposed to the darkness treatment for 8 weeks.
- Group 0 sample size Number of subjects in the control (unexposed) group
- 8
- Group 1 sample size Number of subjects in the case (exposed) group
- 8
Lab analysis
- Sequencing type
- 16S
- 16S variable region One or more hypervariable region(s) of the bacterial 16S gene
- V3-V4
- Sequencing platform Manufacturer and experimental platform used for quantifying microbial abundance
- Illumina
Statistical Analysis
- Data transformation Data transformation applied to microbial abundance measurements prior to differential abundance testing (if any).
- relative abundances
- Statistical test
- Dunn's test
- Kruskall-Wallis
- Significance threshold p-value or FDR threshold used for differential abundance testing (if any)
- 0.05
- MHT correction Have statistical tests be corrected for multiple hypothesis testing (MHT)?
- No
Alpha Diversity
- Shannon Estimator of species richness and species evenness: more weight on species richness
- unchanged
- Chao1 Abundance-based estimator of species richness
- unchanged
- Simpson Estimator of species richness and species evenness: more weight on species evenness
- unchanged
- Richness Number of species
- unchanged
Signature 1
Reviewed Marked as Reviewed by KateRasheed on 2025-8-18
Source: Figure 5c & Supplementary Data 4
Description: Relative abundance of differential genera (highly or lowly expressed in darkness rats compared with control and DL.reuteri rats, P < 0.05), calculated with Kruskal–Wallis test followed by Dunn’s multiple comparison test.
Abundance in Group 1: increased abundance in Darkness
| NCBI | Quality Control | Links |
|---|---|---|
| Clostridium | ||
| Ruminococcaceae UCG-009Ruminococcaceae UCG-009 | ||
| Ruminococcaceae UCG-010Ruminococcaceae UCG-010 | ||
| Family XIII AD3011 groupFamily XIII AD3011 group |
Revision editor(s): Victoria
Signature 2
Reviewed Marked as Reviewed by KateRasheed on 2025-8-18
Source: Figure 5c & Supplementary Data 4
Description: Relative abundance of differential genera (highly or lowly expressed in darkness rats compared with control and DL.reuteri rats, P < 0.05), calculated with Kruskal–Wallis test followed by Dunn’s multiple comparison test.
Abundance in Group 1: decreased abundance in Darkness
| NCBI | Quality Control | Links |
|---|---|---|
| Lactobacillus |
Revision editor(s): Victoria
Experiment 2
Reviewed Marked as Reviewed by KateRasheed on 2025-8-18
Differences from previous experiment shown
Subjects
- Group 0 name Corresponds to the control (unexposed) group for case-control studies
- Darkness
- Group 1 name Corresponds to the case (exposed) group for case-control studies
- Darkness+Limosilactobacillus reuteri
- Group 1 definition Diagnostic criteria applied to define the specific condition / phenotype represented in the case (exposed) group
- Rats in this group were exposed to the darkness treatment for 8 weeks, followed by Limosilactobacillus reuteri administration.
Lab analysis
Statistical Analysis
Alpha Diversity
- Shannon Estimator of species richness and species evenness: more weight on species richness
- unchanged
- Chao1 Abundance-based estimator of species richness
- unchanged
- Simpson Estimator of species richness and species evenness: more weight on species evenness
- unchanged
- Richness Number of species
- unchanged
Signature 1
Reviewed Marked as Reviewed by KateRasheed on 2025-8-18
Source: Figure 5c & Supplementary Data 4
Description: Relative abundance of differential genera (highly or lowly expressed in darkness rats compared with control and DL.reuteri rats, P < 0.05), calculated with Kruskal–Wallis test followed by Dunn’s multiple comparison test.
Abundance in Group 1: increased abundance in Darkness+Limosilactobacillus reuteri
| NCBI | Quality Control | Links |
|---|---|---|
| Lactobacillus |
Revision editor(s): Victoria
Signature 2
Reviewed Marked as Reviewed by KateRasheed on 2025-8-18
Source: Figure 5c & Supplementary Data 4
Description: Relative abundance of differential genera (highly or lowly expressed in darkness rats compared with control and DL.reuteri rats, P < 0.05), calculated with Kruskal–Wallis test followed by Dunn’s multiple comparison test.
Abundance in Group 1: decreased abundance in Darkness+Limosilactobacillus reuteri
| NCBI | Quality Control | Links |
|---|---|---|
| Clostridium | ||
| Ruminococcaceae UCG-009Ruminococcaceae UCG-009 | ||
| Ruminococcaceae UCG-010Ruminococcaceae UCG-010 | ||
| Family XIII AD3011 groupFamily XIII AD3011 group |
Revision editor(s): Victoria
Experiment 3
Reviewed Marked as Reviewed by KateRasheed on 2025-8-18
Differences from previous experiment shown
Subjects
- Group 0 name Corresponds to the control (unexposed) group for case-control studies
- Control & Darkness
- Group 0 sample size Number of subjects in the control (unexposed) group
- 16
Lab analysis
Statistical Analysis
- Statistical test
- LEfSe
- LDA Score above Threshold for the linear discriminant analysis (LDA) score for studies using the popular LEfSe tool
- 2
Signature 1
Reviewed Marked as Reviewed by KateRasheed on 2025-8-18
Source: Figure 5d & e
Description: Cladogram and Genera biomarkers within groups identified by LDA effect size analysis with an LDA score > 2.
Abundance in Group 1: increased abundance in Darkness+Limosilactobacillus reuteri
Revision editor(s): Victoria
Experiment 4
Reviewed Marked as Reviewed by KateRasheed on 2025-8-18
Differences from previous experiment shown
Subjects
- Group 0 name Corresponds to the control (unexposed) group for case-control studies
- Control & Darkness+Limosilactobacillus reuteri
- Group 1 name Corresponds to the case (exposed) group for case-control studies
- Darkness
- Group 1 definition Diagnostic criteria applied to define the specific condition / phenotype represented in the case (exposed) group
- Rats in this group were exposed to the darkness treatment for 8 weeks.
Lab analysis
Statistical Analysis
Signature 1
Reviewed Marked as Reviewed by KateRasheed on 2025-8-18
Source: Figure 5d & e
Description: Cladogram and Genera biomarkers within groups identified by LDA effect size analysis with an LDA score > 2.
Abundance in Group 1: increased abundance in Darkness
Revision editor(s): Victoria
Experiment 5
Reviewed Marked as Reviewed by KateRasheed on 2025-8-18
Differences from previous experiment shown
Subjects
- Group 0 name Corresponds to the control (unexposed) group for case-control studies
- Darkness & Darkness+Limosilactobacillus reuteri
- Group 1 name Corresponds to the case (exposed) group for case-control studies
- Control
- Group 1 definition Diagnostic criteria applied to define the specific condition / phenotype represented in the case (exposed) group
- Rats in this group were not exposed to the darkness treatment.
Lab analysis
Statistical Analysis
Signature 1
Reviewed Marked as Reviewed by KateRasheed on 2025-8-18
Source: Figure 5d & e
Description: Cladogram and Genera biomarkers within groups identified by LDA effect size analysis with an LDA score > 2.
Abundance in Group 1: increased abundance in Control
Revision editor(s): Victoria
Retrieved from "https://bugsigdb.org/w/index.php?title=37422471&oldid=209095"
